Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.45 USD
Change Today 0.00 / 0.00%
Volume 22.0
TPI On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

tianyin pharmaceutical co in (TPI) Snapshot

Open
$0.45
Previous Close
$0.45
Day High
$0.45
Day Low
$0.45
52 Week High
01/5/15 - $0.78
52 Week Low
03/31/15 - $0.38
Market Cap
13.2M
Average Volume 10 Days
14.2K
EPS TTM
$-0.06
Shares Outstanding
29.4M
EX-Date
05/11/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TIANYIN PHARMACEUTICAL CO IN (TPI)

Related News

No related news articles were found.

tianyin pharmaceutical co in (TPI) Related Businessweek News

No Related Businessweek News Found

tianyin pharmaceutical co in (TPI) Details

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company, develops, manufactures, markets, and sells patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and active pharmaceutical ingredients in the People’s Republic of China. It offers a portfolio of 58 products for use in the therapeutic areas of internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, and orthopedics. The company markets its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies. Tianyin Pharmaceutical Co., Inc. was founded in 1994 and is headquartered in Chengdu, the People’s Republic of China.

1,000 Employees
Last Reported Date: 12/9/14
Founded in 1994

tianyin pharmaceutical co in (TPI) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $100.0K
Chief Operating Officer, Chief Advisor of Sal...
Total Annual Compensation: $80.0K
Chief Technology Officer
Total Annual Compensation: $80.0K
Vice President of Marketing & Sales
Total Annual Compensation: $80.0K
Compensation as of Fiscal Year 2014.

tianyin pharmaceutical co in (TPI) Key Developments

Tianyin Pharmaceutical Receives Non-Compliance Notice From NYSE MKT

On May 21, 2015, Tianyin Pharmaceutical Co, Inc. received a notice from the NYSE MKT Staff indicating that the Company is below certain of the continued listing standards of the NYSE MKT (the “Exchange”) as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2015 (the “Form 10-Q”) beyond the extended filing due date of May 20, 2015. Currently the Company is working diligently with the auditor to compile and disseminate the information required to be included in the Form 10-Q, as well as the required review of the Company’s financial information. The Company expects to file the Form 10-Q as soon as possible and before the deadline set by the Exchange.

Tianyin Pharmaceutical Co., Inc. announced delayed 10-Q filing

On 05/15/2015, Tianyin Pharmaceutical Co., Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Tianyin Pharmaceutical Receives Notice Of Non-Compliance With NYSE MKT Continued Listing Requirements

Tianyin Pharmaceutical Inc. received notice on February 24, 2015 from the NYSE MKT LLC (the "Exchange") indicating that the Company is below certain of the Exchange's continued listing standards, as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing of its Quarterly Report on Form 10-Q for the period ended December 31, 2014. Under NYSE MKT rules, until the Company files the Form 10-Q, its common stock will remain listed on the NYSE MKT under the symbol "TPI," but will be assigned an ".LF" indicator to signify late filing status. Five business days following the receipt of the noncompliance letter, the Company will be added to the list of NYSE MKT noncompliant issuers on the website and the indicator will be disseminated with the Company's ticker symbol. The indicator will be removed when the Company has regained compliance with all applicable continued listing standards. In order to maintain its listing, the Company must submit a plan of compliance by March 10, 2015 addressing how it intends to regain compliance with Sections 134 and 1101 of the NYSE MKT Company Guide by May 22, 2015. If the plan is accepted, the Company may be able to continue its listing but will be subject to periodic reviews by the Exchange. If the plan is not accepted or if it is accepted but the Company is not in compliance with the continued listing standards by May 22, 2015, or if the Company does not make progress consistent with the plan, the Exchange will initiate delisting procedures as appropriate. The Company intends to submit a compliance plan on or before the deadline set by the Exchange. Currently the Company is working diligently with the auditor to compile and disseminate the information required to be included in the Form 10-Q, as well as the required review of the Company's financial information. The Company expects to file the Form 10-Q as soon as possible and before the deadline set by the Exchange.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPI:US $0.45 USD 0.00

TPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ImmunoCellular Therapeutics Ltd $0.48 USD +0.0034
Northwest Biotherapeutics Inc $8.40 USD +0.15
Opexa Therapeutics Inc $0.57 USD -0.04
StemCells Inc $0.68 USD -0.017
View Industry Companies
 

Industry Analysis

TPI

Industry Average

Valuation TPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.4x
Price/Book 0.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANYIN PHARMACEUTICAL CO IN, please visit www.tianyinpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.